Sonnet Biotherapeutics Holdings Inc Total Assets
Sonnet Biotherapeutics Holdings Inc total assets. Based on the latest financial reports, Sonnet Biotherapeutics Holdings Inc (SONN) holds total assets worth $2.06 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Sonnet Biotherapeutics Holdings Inc for the company's overall valuation and market capitalisation.
Total Assets of Sonnet Biotherapeutics Holdings Inc (2007–2025)
Total assets of Sonnet Biotherapeutics Holdings Inc from 2007 to 2025. This chart illustrates how Sonnet Biotherapeutics Holdings Inc's total assets have evolved over time, based on quarterly financial data. See SONN live share price for real-time trading data and today's change.
Sonnet Biotherapeutics Holdings Inc - Asset Composition Analysis
Sonnet Biotherapeutics Holdings Inc Total Assets Breakdown (September 2025)
Sonnet Biotherapeutics Holdings Inc total assets breakdown as of September 2025. Sonnet Biotherapeutics Holdings Inc's total assets of $2.06 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Sonnet Biotherapeutics Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SONN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sonnet Biotherapeutics Holdings Inc's current assets represent 96.4% of total assets in 2025, an increase from 0.5% in 2007.
- Cash Position: Cash and equivalents constituted 34.4% of total assets in 2025, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sonnet Biotherapeutics Holdings Inc Competitors by Total Assets
Key competitors of Sonnet Biotherapeutics Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Sonnet Biotherapeutics Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.26 | 1.65 | 1.62 |
| Quick Ratio | 0.26 | 1.65 | 1.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.78 Million | $2.02 Million | $2.91 Million |
Sonnet Biotherapeutics Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Sonnet Biotherapeutics Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 437.1% |
| Total Assets | $14.88 Million |
| Market Capitalization | $8.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sonnet Biotherapeutics Holdings Inc's assets below their book value (0.58x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sonnet Biotherapeutics Holdings Inc's assets grew by 437.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sonnet Biotherapeutics Holdings Inc (2007–2025)
The table below shows the annual total assets of Sonnet Biotherapeutics Holdings Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $14.88 Million | +437.15% |
| 2024-09-30 | $2.77 Million | -48.96% |
| 2023-09-30 | $5.43 Million | -6.87% |
| 2022-09-30 | $5.83 Million | -79.89% |
| 2021-09-30 | $28.99 Million | +262.68% |
| 2020-09-30 | $7.99 Million | +20009.69% |
| 2019-09-30 | $39.75K | -99.87% |
| 2018-12-31 | $29.79 Million | -1.29% |
| 2017-09-30 | $30.18 Million | -9.86% |
| 2016-09-30 | $33.49 Million | -20.66% |
| 2015-12-31 | $42.21 Million | +17.92% |
| 2015-09-30 | $35.79 Million | +78.18% |
| 2013-12-31 | $20.09 Million | 0.00% |
| 2013-09-30 | $20.09 Million | +264.92% |
| 2012-09-30 | $5.50 Million | -99.61% |
| 2011-09-30 | $1.41 Billion | +97209.57% |
| 2009-09-30 | $1.45 Million | -34.67% |
| 2008-09-30 | $2.23 Million | -41.82% |
| 2007-09-30 | $3.82 Million | -- |
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more